Scrip: industry news and insights
Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
31 Jan 2023
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial...
More than two-fifths of new drugs approved in the US last year were orphan drugs, and there are more than 4,500 drugs in active development for rare diseases. Effective orphan drug legislation and incentivization programs introduced gradually around the world since the 1980s mean rare diseases are no longer a rare sighting in the pharma industry pipeline, as this infographic illustrates.
Scrip: industry news and insights
31 Jan 2023
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial...
Scrip: industry news and insights
31 Jan 2023
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440...
Scrip: industry news and insights
31 Jan 2023
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: